ImmunologybioRxivPreprint
Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer
C. Tiraboschi, L. Gentilini, E. Corapi…·D. Compagno
This paper identifies Galectin-3 as a key immune checkpoint in prostate cancer that Docetaxel inhibits, enhancing immunotherapy effectiveness through Th1 response promotion and CD8+ T cell activation.
DOI 10.1101/763409